Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07197762 · ClinicalTrials.gov registry record · Phase 4
MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults
A Phase 4 study of Neisseria Meningitidis, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 125
- Enrollment target
- 2
- Study locations
NCT07197762: Recruiting Phase 4 study of Neisseria Meningitidis, sponsored by Emory University.
NCT07197762 is a Phase 4 study of Neisseria Meningitidis that is actively recruiting participants, run by Emory University. The registered enrollment target is 125 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07197762, a Phase 4 study of Neisseria Meningitidis, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 125 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to determine the immunogenicity of certain vaccines in protecting against meningitis B (MenB) in young adults who have previously received a different MenB vaccine. The main questions it aims to answer are: * How many participants are protected against four key types of MenB bacteria before and after getting the new vaccine? * How strong is the immune response after vaccination, and how many people show a noticeable boost in immune response?
Primary Outcome
Percentage of participants who are seroprotected, defined as a human serum bactericidal antibody assay (hSBA) titer ≥LLOQ-Lower limit of quantification (1:16 for strain A22 and 1:8 for strains A56, B24, and B44) for each of the 4 primary MenB indicator strains (A22, A56, B24, and B44) with Trumenba or Penbraya. Serum samples from V1 and V2 will be shipped in batches to Pfizer, where hSBA assays will be performed.
Conditions Studied
Interventions
- BIOLOGICAL Trumenba
- BIOLOGICAL PENBRAYA
Study Locations (2)
Georgia
- Emory Children's Center-Vaccine Research Clinic - Atlanta
- Hope Clinic - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-11-04 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
What NCT07197762 shows while recruiting
NCT07197762 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Neisseria Meningitidis appearing as the primary indexed condition, and to 2 interventions - of which Trumenba is the first listed.
NCT07197762 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT07197762 about?
NCT07197762 is a clinical study titled "MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults". The goal of this clinical trial is to determine the immunogenicity of certain vaccines in protecting against meningitis B (MenB) in young adults who have previously received a different MenB vaccine. The main questions it aims to answer are: * How many participants are protected against four key t...
What is the current status of trial NCT07197762?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 125 participants. The study started on 2025-11-04. Estimated completion is 2026-12.
What conditions does trial NCT07197762 study?
This clinical trial studies the following conditions: Neisseria Meningitidis.
What interventions are being tested in trial NCT07197762?
The interventions under investigation include: Trumenba (BIOLOGICAL), PENBRAYA (BIOLOGICAL).
Who is sponsoring clinical trial NCT07197762?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07197762 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neisseria Meningitidis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07197762's enrollment target sits among peer trials
125 647th of 2000 higher than 1,346 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
COMPLETED · Phase 3
-
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI